The clinical trials industry has never had more tools, data, or innovation aimed at accelerating timelines. In fact, if you walk the floor of any industry event you’ll see “acceleration” everywhere. It’s in the messaging, the booths, the product demos, and the promises. From AI-driven feasibility models to precision targeting, digital recruitment strategies, and decentralized trial technologies, the system appears more advanced and faster than ever. Yet approximately 80–85% of clinical trials
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Medidata Launches Medidata Plus AI Layer to Standardize Clinical Trial Data and Workflows
What You Should Know
Medidata, a Dassault Systèmes brand, has launched Medidata Plus, an embedded clinical artificial intelligence layer designed to unlock scalable AI capabilities across the entire Medidata Platform.While 92% of life sciences decision-makers plan to increase AI spend, only 29% report AI meets their expectations. Medidata Plus eliminates disparate point solutions, providing a predictable, standardized data layer across the trial lifecycle.Automates Electronic Data Capture
Read More
Cheiron Raises $8M to Launch AI-Native the Operating System for Drug Programs
What You Should Know
AI-native life sciences platform Cheiron has secured $8M in seed funding led by Menlo Ventures, with Venky Ganesan joining the board.Strategic backers include Moderna co-founder Robert Langer, former Pfizer CMO Freda Lewis-Hall, Chai Discovery CEO Josh Meier, former Starbucks CEO Laxman Narasimhan, and former Apple AI chief John Giannandrea.Cheiron is designed to replace fragmented spreadsheets, papers, and filings by representing an entire drug development lifecycle as a
Read More
Flatiron Health Expands Global Oncology Network via First Partnership in Scotland with NHSGGC
What You Should Know
Flatiron Health UK has partnered with NHS Greater Glasgow and Clyde (NHSGGC), Scotland's largest health board, establishing Flatiron's first research footprint in the Scottish healthcare system.The NHSGGC collaboration contributes to a nearly 70% expansion of Flatiron's international oncology network over the past year, which now spans more than 50 leading sites across the UK, Germany, and Japan.Flatiron's global oncology dataset is constructed from over six million
Read More
Bluesight Partners with Pfizer to Integrate SmartDose™ Source-Tagged Medications into KitCheck
What You Should Know
Hospital intelligence leader Bluesight has partnered with Pfizer Global Hospital & Biosimilars to integrate Pfizer’s SmartDose™ RFID-enabled medications into the KitCheck inventory management platform.The partnership shifts RFID tagging upstream to the point of manufacture, allowing hospital pharmacies to procure pre-tagged, pre-encoded, and pre-associated medications right out of the box.SmartDose™ marks an industry first by utilizing automated readback verification
Read More
Chai Discovery Raises $400M to Accelerate AI-Driven Molecular Design Platform
What You Should Know
Structural biology and AI drug design pioneer Chai Discovery has announced a $400M Series C funding round, valuing the company at $3.8 billion just two years after its 2024 founding.The heavily oversubscribed round was led by Index Ventures, alongside Kleiner Perkins, Sequoia Capital, and Dimension, with strategic backing from existing investors OpenAI and Thrive Capital.Moving past legacy computational screening methods, Chai’s generative platform engineers entirely de
Read More
HHS and Secretary Robert F. Kennedy, Jr. Launch Operation Trialblazer to Modernize Clinical Trials
What You Should Know
The U.S. Department of Health and Human Services (HHS), under Secretary Robert F. Kennedy, Jr., has unveiled "Operation Trialblazer," a sweeping, department-wide initiative designed to bring clinical research and investment back to the United States.The strategic pivot addresses an alarming competitive gap: China's global share of Phase 1 trials surpassed the U.S. for the first time in 2021, and in 2024, China exceeded the U.S. in total clinical trial registrations with
Read More
What Senior Leaders Actually Need to Know About Scaling Digital in
Pharma
Digital transformation in pharma usually starts off strong, big vision, budget gets approved, everyone’s aligned, but scaling it is where things get messy. At the leadership level, this really becomes an orchestration problem. It’s like trying to expand a manufacturing plant while everything is still running. You can’t pause production, you can’t mess up compliance, and you definitely can’t create chaos on the floor. Scaling digital works the same way. You’re layering in new systems, new
Read More
Why Validation is Becoming the Proving Ground for AI in Life Sciences
The measurable business impact of AI is lagging way behind the hype. McKinsey found that about 80% of companies now use gen AI in at least one function, yet only about 40% are seeing EBIT impact from it. Of that 40%, most of the measurable impact falls under 5%. Another concerning finding is that nearly half of the IT organizations surveyed plan to increase their investment in gen AI, yet investment is actually decreasing in the foundations needed to scale gen AI, like secure infrastructure,
Read More
Leveraging Real-World Data for Proactive Protocol Design
Clinical trials have grown more complex than ever before. Protocols are becoming more specialized, endpoints more refined, and eligibility criteria narrower and more precise. At the same time, development programs are expected to move faster and operate with greater efficiency. Despite this dual pressure, feasibility projections often rely on high-level estimates or investigator recall rather than validated assessments of patients who truly meet protocol criteria in a real-world clinical
Read More
